Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

Clive S. Zent, Timothy G. Call, Tait D. Shanafelt, Renee C. Tschumper, Diane F. Jelinek, Deborah A. Bowen, Charla R. Secreto, Betsy R. LaPlant, Brian F. Kabat, Neil E. Kay

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Abstract

BACKGROUND. Patients with chronic lymphocytic leukemia (CLL) usually are treated only for progressive disease. However, the discovery of biologic predictors of a high risk of disease progression, together with the development of newer, more targeted therapies, could change this paradigm. In this phase 2 study, the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab. METHODS. Patients were eligible for treatment if they were 1) previously untreated, 2) had no National Cancer Institute-Working Group 1996 criteria for treatment, and 3) had at least 1 marker of high-risk disease 17p13-, 11q22-, or a combination of unmutated IgVH and CD38+/ZAP70+). Treatment consisted of subcutaneous alemtuzumab (initial dose escalation followed by 30 mg on Monday, Wednesday, and Friday for 4 weeks) and intravenous rituximab (375 mg/m2 per week 34 doses). All patients received Pneumocystis pneumonia and herpes virus prophylaxis and were monitored for cytomegalovirus reactivation. RESULTS. Twenty-seven of 30 patients (90%) responded to therapy with 11 (37%) complete responses (CRs). Five patients (17%) patients who had a CR had no detectable minimal residual disease. The median response duration was 14.4 months, and only 9 patients required retreatment for progressive disease at the time of the current report (median follow-up, 17.6 months). Study patients had a significantly longer time from diagnosis to first treatment for CLL according to conventional indications than a comparison cohort with similar biologic risk profiles. CONCLUSIONS. The therapy regimen used was safe and effective for early treatment of patients with high-risk CLL. Further studies will be required to determine whether this early treatment strategy decreases morbidity and mortality for high-risk CLL.

Original languageEnglish (US)
Pages (from-to)2110-2118
Number of pages9
JournalCancer
Volume113
Issue number8
DOIs
StatePublished - Oct 15 2008

Keywords

  • Alemtuzumab
  • Chronic lymphocytic leukemia
  • Early stage
  • High risk
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab'. Together they form a unique fingerprint.

Cite this